Trial Profile
A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms TRIPLE NEGATIVE
- 22 Jul 2022 Status changed from discontinued to completed.
- 03 Oct 2018 Status changed from recruiting to discontinued.
- 23 Nov 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.